Los Angeles, CA (PRWEB) January 05, 2012
Lerner Medical Devices, Inc. (LMD) announced today that Levia®, an innovative medical device providing Personal Targeted Phototherapy®, received a Medical Device License from Health Canada, Medical Devices Bureau. This license allows LMD to commence product sales in Canada. Levia provides targeted Ultraviolet B (UVB) light – a safe and effective non-drug option for the self-treatment of psoriasis – in the privacy and convenience of a patient’s home.
Cleared by the FDA, Levia enables physician control of dosimetry. Levia's technology includes two proprietary beam-delivery attachments – the LiteSpot™ and LiteBrush™- that ensure precise delivery of UVB light to affected areas of skin and scalp. Available as a prescription device, Levia permits patients to treat themselves rapidly and safely with UVB, a proven, non-systemic therapy, effective for more than 85% of psoriasis sufferers.
“We want to establish proven, UVB phototherapy as a practical, first line treatment alternative for the majority of patients with mild to moderate psoriasis,” said Gary Stapleton, President and Chief Executive Officer, LMD. “UVB is well tolerated, effective and has an excellent side-effect profile for long term use. Patients can use the LiteBrush with its innovative, fiber-optic bristles to deliver UVB to the scalp, an area seldom selected for UVB treatment because hair creates a barrier to light.”
“UVB phototherapy is suitable for more than 85% of psoriasis patients, yet less than 5% of them are being treated with it,” said Ethan Lerner, M.D., Ph.D., Associate Professor of Dermatology at Harvard Medical School and Massachusetts General Hospital, and LMD ’s founder. “We believe this is because UVB phototherapy, as conventionally delivered in a clinical setting, is relatively inconvenient and expensive for the patient, involving multiple weekly visits over extended periods.”
Dr. Lerner said, “Delivery of UVB phototherapy at home, with patients treating themselves under the close supervision of their physician, makes compliance with extended treatment regimens easier to maintain. Levia and Personal Targeted Phototherapy introduce a new class of technology and treatment which will facilitate the accelerated adoption of home UVB phototherapy.”
Surprising Psoriasis Facts
There are more psoriasis patients than those with Alzheimer’s, Parkinson’s and other more publicized medical conditions. Psoriasis sufferers have higher incidence levels of Crohn’s, multiple sclerosis, metabolic syndrome and cardiovascular disease than the general population. Psoriasis has a significant psychosocial component; patients frequently perceive the effect to be more severe than the physician’s clinical assessment.
ABOUT LERNER MEDICAL DEVICES, INC
Lerner Medical Devices, Inc. (LMD) develops, manufactures and markets phototherapeutic devices that utilize advanced optical technology to treat photo-responsive skin conditions and diseases. Founded in 2001, LMD developed the LiteBrush™ technology designed for treating scalp psoriasis. The LiteBrush uses fiber optic “bristles,” configured like a hairbrush, to deliver UVB phototherapy directly to the scalp.
Levia® delivers Personal Targeted Phototherapy® for the self-treatment of psoriasis, in the privacy and convenience of a patient’s home. Levia features easy to use software for physician dosimetry control and includes two proprietary beam delivery attachments, the LiteBrush and the LiteSpot™, which ensure precise and safe delivery of therapeutic UVB light. To learn more about Levia and Lerner Medical Devices, visit: http://www.mylevia.com
Find Levia on Facebook: http://www.facebook.com/mylevia
Follow Levia on Twitter: http://www.twitter.com/mylevia
Follow Nurse Linda’s blog: http://asknurselinda.tumblr.com
Watch Levia on YouTube: http://www.youtube.com/Levia2010